Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : MDimune
Deal Size : Undisclosed
Deal Type : Collaboration
PCI Biotech and MDimune Announce Research Collaboration Agreement
Details : This collaboration is an additional mark of interest from a cutting-edge biotech company developing therapies with emerging advanced technologies, with a large potential in future medicine
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : MDimune
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PCI Biotech: Update on the RELEASE trial
Details : PCI of gemcitabine with Amphinex shows an innovative treatment that could potentially produce significant local tumour response in patients. The study is well designed to demonstrate the potential benefit of Amphinex induced PCI of gemcitabine in bile du...
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PCI Biotech: Update on Regulatory Interactions for the RELEASE Trial
Details : The interaction with the FDA and EMA initiated to explore the opportunity for a modified study design to address the retention risk in the control arm of the RELEASE study of Amphinex (Fimaporfin).
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The fimaChem treatment regimen consists of an intravenous injection of fimaporfin, a photosensitiser drug followed four days later by an intravenous infusion of gemcitabine and a laser light application in the bile duct.
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PCI Biotech: First US Patient Enrolled in the Fima Chem Pivotal RELEASE Study
Details : First US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients.
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PCI Biotech: European Patent for Treatment of Bile Duct Cancer with the FimaChem Technology
Details : The European patent covers the intended use of fimaChem in combination with gemcitabine for the treatment of cholangiocarcinoma (bile duct cancer).
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
PCI Biotech: Preclinical Research Collaboration with Big Pharma Ended
Details : Company's decision not to enter into a definitive agreement is primarily based on a strategic evaluation of current development needs. Results have continued to be achieved with the fimaNAc platform in the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fimaporfin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PCI Biotech: Publication of Case Report Series from the Phase I Study in Bile Duct Cancer
Details : PCI Biotech has announced case report series from the Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International O...
Product Name : Amphinex
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 19, 2020
Lead Product(s) : Fimaporfin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable